Elisabetta Barresi

List of Publications by Year
in descending order

47	1,106	304743	414414
papers	citations	22 h-index	32 g-index

47	47	47	1467
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cancer Immunotherapy: An Overview on Small Molecules as Inhibitors of the Immune Checkpoint PD-1/PD-L1 (2015-2021). Mini-Reviews in Medicinal Chemistry, 2022, 22, .	2.4	3
2	Essential Principles and Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging. Current Medicinal Chemistry, 2022, 29, 4862-4890.	2.4	9
3	Carbonic Anhydrase Activators for Neurodegeneration: An Overview. Molecules, 2022, 27, 2544.	3.8	17
4	Translocator Protein 18-kDa: a promising target to treat neuroinflammation-related degenerative diseases. Current Medicinal Chemistry, 2022, 29, .	2.4	4
5	Multiple Topoisomerase I (TopoI), Topoisomerase II (TopoII) and Tyrosyl-DNA Phosphodiesterase (TDP) inhibitors in the development of anticancer drugs. European Journal of Pharmaceutical Sciences, 2021, 156, 105594.	4.0	31
6	Novel positive allosteric modulators of A_{2B} adenosine receptor acting as bone mineralisation promoters. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 287-295.	5.2	12
7	An update into the medicinal chemistry of translocator protein (TSPO) ligands. European Journal of Medicinal Chemistry, 2021, 209, 112924.	5.5	31
8	Two mixed valence diruthenium(<scp>ii</scp>,<scp>iii</scp>) isomeric complexes show different anticancer properties. Dalton Transactions, 2021, 50, 9643-9647.	3.3	28
9	Carbonic anhydrase activation profile of indole-based derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 1783-1797.	5.2	3
10	Tetrahydroquinazole-based secondary sulphonamides as carbonic anhydrase inhibitors: synthesis, biological evaluation against isoforms I, II, IV, and IX, and computational studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 1874-1883.	5.2	4
11	De novo Neurosteroidogenesis in Human Microglia: Involvement of the 18 kDa Translocator Protein. International Journal of Molecular Sciences, 2021, 22, 3115.	4.1	15
12	Allosterism vs. Orthosterism: Recent Findings and Future Perspectives on A2B AR Physio-Pathological Implications. Frontiers in Pharmacology, 2021, 12, 652121.	3.5	5
13	The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities. Journal of Medicinal Chemistry, 2021, 64, 3508-3545.	6.4	51
14	Strategies for the Improvement of Metal-Based Chemotherapeutic Treatments. Biomedicines, 2021, 9, 504.	3.2	35
15	Inhibition studies on carbonic anhydrase isoforms I, II, IV and IX with N-arylsubstituted secondary sulfonamides featuring a bicyclic tetrahydroindazole scaffold. European Journal of Medicinal Chemistry, 2021, 220, 113490.	5.5	9
16	Drug Repurposing Meets DNA Independent Pathways: Targeting Alternative Substrates for Anticancer Therapy. Current Topics in Medicinal Chemistry, 2021, 21, 2767-2770.	2.1	0
17	Enriching the Arsenal of Pharmacological Tools against MICAL2. Molecules, 2021, 26, 7519.	3.8	1
18	A mixed-valence diruthenium(ii,iii) complex endowed with high stability: from experimental evidence to theoretical interpretation. Dalton Transactions, 2020, 49, 14520-14527.	3.3	25

#	Article	IF	Citations
19	Targeting the KRAS oncogene: Synthesis, physicochemical and biological evaluation of novel G-Quadruplex DNA binders. European Journal of Pharmaceutical Sciences, 2020, 149, 105337.	4.0	15
20	Novel 2-substituted-benzimidazole-6-sulfonamides as carbonic anhydrase inhibitors: synthesis, biological evaluation against isoforms I, II, IX and XII and molecular docking studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 1697-1710.	5.2	28
21	Discovery of Pyrido[3â€²,2â€²:5,6]thiopyrano[4,3-d]pyrimidine-Based Antiproliferative Multikinase Inhibitors. ACS Medicinal Chemistry Letters, 2019, 10, 457-462.	2.8	3
22	Long lasting inhibition of Mdm2-p53 interaction potentiates mesenchymal stem cell differentiation into osteoblasts. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 737-749.	4.1	10
23	Unbinding of Translocator Protein 18 kDa (TSPO) Ligands: From in Vitro Residence Time to in Vivo Efficacy via in Silico Simulations. ACS Chemical Neuroscience, 2019, 10, 3805-3814.	3.5	22
24	Benzothiopyranoindole- and pyridothiopyranoindole-based antiproliferative agents targeting topoisomerases. European Journal of Medicinal Chemistry, 2019, 165, 46-58.	5.5	5
25	Studies on enantioselectivity of chiral 4-acetylamino-6-alkyloxy-2-alkylthiopyrimidines acting as antagonists of the human A₃ adenosine receptor. MedChemComm, 2018, 9, 81-86.	3.4	6
26	Novel fluorescent triazinobenzimidazole derivatives as probes for labelling human A1 and A2B adenosine receptor subtypes. Bioorganic and Medicinal Chemistry, 2018, 26, 5885-5895.	3.0	6
27	4-Substituted Benzenesulfonamides Incorporating Bi/Tricyclic Moieties Act as Potent and Isoform-Selective Carbonic Anhydrase II/IX Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 5765-5770.	6.4	18
28	Residence Time, a New parameter to Predict Neurosteroidogenic Efficacy of Translocator Protein (TSPO) Ligands: the Case Study of N,Nâ€Dialkylâ€2â€arylindolâ€3â€ylglyoxylamides. ChemMedChem, 2017, 12, 1275-1278.	3.2	9
29	Exploiting the 4-Phenylquinazoline Scaffold for the Development of High Affinity Fluorescent Probes for the Translocator Protein (TSPO). Journal of Medicinal Chemistry, 2017, 60, 7897-7909.	6.4	13
30	Iminothioethers as Hydrogen Sulfide Donors: From the Gasotransmitter Release to the Vascular Effects. Journal of Medicinal Chemistry, 2017, 60, 7512-7523.	6.4	48
31	TSPO PIGA Ligands Promote Neurosteroidogenesis and Human Astrocyte Well-Being. International Journal of Molecular Sciences, 2016, 17, 1028.	4.1	32
32	TSPO ligand residence time: a new parameter to predict compound neurosteroidogenic efficacy. Scientific Reports, 2016, 6, 18164.	3.3	53
33	Lead Optimization of 2-Phenylindolylglyoxylyldipeptide Murine Double Minute (MDM)2/Translocator Protein (TSPO) Dual Inhibitors for the Treatment of Gliomas. Journal of Medicinal Chemistry, 2016, 59, 4526-4538.	6.4	28
34	Toward PET imaging of A2B adenosine receptors: a carbon-11 labeled triazinobenzimidazole tracer. Nuclear Medicine and Biology, 2016, 43, 309-317.	0.6	10
35	Sulfonamides incorporating heteropolycyclic scaffolds show potent inhibitory action against carbonic anhydrase isoforms I, II, IX and XII. Bioorganic and Medicinal Chemistry, 2016, 24, 921-927.	3.0	18
36	Long lasting MDM2/Translocator protein modulator: a new strategy for irreversible apoptosis of human glioblastoma cells. Oncotarget, 2016, 7, 7866-7884.	1.8	17

#	Article	IF	Citations
37	Targeting the 18-kDa translocator protein: recent perspectives for neuroprotection. Biochemical Society Transactions, 2015, 43, 559-565.	3.4	32
38	TSPO ligand residence time influences human glioblastoma multiforme cell death/life balance. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 383-398.	4.9	22
39	Deepening the Topology of the Translocator Protein Binding Site by Novel N,N-Dialkyl-2-arylindol-3-ylglyoxylamides. Journal of Medicinal Chemistry, 2015, 58, 6081-6092.	6.4	31
40	Structureâ€“Activity Relationship Refinement and Further Assessment of 4-Phenylquinazoline-2-carboxamide Translocator Protein Ligands as Antiproliferative Agents in Human Glioblastoma Tumors. Journal of Medicinal Chemistry, 2014, 57, 2413-2428.	6.4	41
41	Allosteric modulators of human A2B adenosine receptor. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 1194-1203.	2.4	27
42	Apoptosis Therapy in Cancer: The First Single-molecule Co-activating p53 and the Translocator Protein in Glioblastoma. Scientific Reports, 2014, 4, 4749.	3.3	62
43	Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: A Suitable Scaffold for the Development of Noncamptothecin Topoisomerase I (Top1) Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 7458-7462.	6.4	43
44	Arylthioamides as H₂S Donors: <scp>l</scp>-Cysteine-Activated Releasing Properties and Vascular Effects in Vitro and in Vivo. ACS Medicinal Chemistry Letters, 2013, 4, 904-908.	2.8	144
45	Modulation of A2B adenosine receptor by 1-Benzyl-3-ketoindole derivatives. European Journal of Medicinal Chemistry, 2013, 69, 331-337.	5.5	28
46	Benzofuroxane Derivatives as Multi-Effective Agents for the Treatment of Cardiovascular Diabetic Complications. Synthesis, Functional Evaluation, and Molecular Modeling Studies. Journal of Medicinal Chemistry, 2012, 55, 10523-10531.	6.4	24
47	3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: A Novel Template for the Design of Highly Selective A_{2B} Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2012, 55, 1490-1499.	6.4	28